7th Symposium on General Population Screening for T1D
November 14-15, 2024
Barbara Davis Center for Diabetes
The symposium aims to explore the expanding evidence and current international efforts to identify pre-symptomatic T1D, emphasizing the potential benefits such as delayed progression and prevention of complications. Through expert panels and case studies, the event will also address the challenges of monitoring and supporting children with early-stage T1D, as well as the combined screening for both T1D and celiac disease. The discussions will conclude with future directions for screening, highlighting the need for coordinated efforts and policy guidance.
Target Audience: Healthcare professionals including MD, DO, nurses, social workers, and dieticians; researchers in the area of screening, monitoring, and prevention of diabetes; lay representatives of patient organizations and representatives of funding agencies.
Learning Objectives:
- • Review the significance of early detection and intervention for T1D
- • Explain islet autoimmunity screening methods
- • Explain the process of positive screening result confirmation
- • Discuss the role of clinical trials and FDA-approved interventions in delaying onset of symptomatic T1D
- • Collaborate with interdisciplinary teams to outline a comprehensive care plan for high-risk individuals
*Open to all Anschutz Medical Campus faculty and staff.
Please use this link for administrative support
November 14th Symposium on General Population Screening for T1D
8:00-8:05 Welcome and Introduction - Marian Rewers
8:05-8:35 KEYNOTE LECTURE: Screening for type 1 diabetes: EDENT1FI – Chantal Mathieu
SESSION 1: EVIDENCE FOR EXPANDING SCREENING FOR PRE-SYMPTOMATIC T1D
8:35-8:50 Screening relatives of people with T1D – Desmond Schatz
8:50-9:05 Evidence from general population screening in USA – Marian Rewers
9:05-9:30 Evidence from Fr1da and GPPAD – Anette Ziegler
9:20-9:35 Panel discussion
9:35-9:50 Coffee break
SESSION 2: CURRENT INTERNATIONAL GENERAL POPULATION SCREENING PROGRAMS
9:50-10:05 Scandinavian programs – Daniel Agardh
10:05-10:20 Australian National Screening – Kirstine Bell
10:20-10:35 Antibody Detection Israeli Research (ADIR) – Tal Oron
10:35-10:50 Italian national program – Emanuele Bosi
10:50-11:05 The U.K. programs – Parth Narendran
11:05-11:20 Panel discussion
SESSION 3: EXPERT PANEL: WHO SHOULD BE SCREENED FOR EARLY T1D?10:05-10:20 Australian National Screening
11:20-11:35 People with High T1D GRS – Suna Onengut-Gumuscu
11:35-11:45Early Check Study – Jennifer Law
11:45-12:00 People with Personal/Family History of Autoimmunity – Marisa Stahl 12:00-12:30 Lunch
SESSION 4: CURRENT U.S. GENERAL POPULATION SCREENING PROGRAMS
12:30-12:45 Autoimmunity Screening for Kids (ASK) - Cristy Geno Rasmussen
12:45-1:00 Early Detection Pilot Clinic Program – Anastasia Albanese-O’Neill
1:00-1:15 PLEDGE, Sanford Health – Kurt Griffin
1:15-1:30 CASCADE - William Hagopian
1:30-2:00 Panel discussion
2:00-2:15 Coffee break
SESSION 5: BENEFITS OF SCEENING FOR PRE-SYMPTOMATIC T1D
2:15-2:30 Prevention of DKA - Laura Jacobsen
2:30-2:45 Preservation of residual insulin secretion - Emily Simms
2:45-3:00 Benefits of early education - Flor Sepulveda
3:00-3:30 Panel discussion
SESSION 6: COST-EFFECTIVENESS OF POPULATION SCREENING FOR T1D
3:30-3:45 USA - Brett McQueen
3:45-4:00 Germany - Katharina Schoder
4:00-4:15 The U.K. – Richard Oram 4:15-4:30 Panel discussion November 15th Symposium on General Population Screening for T1D
OPENING REMARKS 8:00 – 8:10
SESSION 7: CHALLENGES OF GENERAL POPULATION SCEENING FOR EARLY T1D
8:10-8:25 Primary Care Pediatrics perspective – Martha Middlemist
8:25-8:40 Parent Perspective – Honora Burnett
8:40-8:55 Pediatric Endocrinologist perspective – Shideh Majidi
8:55-9:15 Panel discussion
SESSION 8: CHALLENGES OF MONITORING CHILDREN WITH STAGE 1 OR STAGE 2 T1D
9:15-9:30 Interventions to increase engagement in confirmation and monitoring – Holly O’Donnell
9:30-9:45 Optimal frequency and content of monitoring - Kimberly Bautista
9:45-10:00 PCP, diabetes clinic, and parents – who is responsible for monitoring? - Brigitte Frohnert
10:00-10:15 Transition to clinical care Kimber Simmons
10:15-10:30 Panel discussion
10:30-10:45 Coffee break
SESSION 9: COMMUNITY SUPPORT FOR SCREENING
10:45-11:00 Effective approaches to increase community awareness of T1D – Rick Bacher
11:00-11:15 Early T1D vs early T2D screening and monitoring – Kristen Nadeau
11:15-11:30 Patient/family experience panel - Debra Franco & Ann King 11:30-12:00 Panel Discussion 12:00-12:30 Lunch
SESSION 10: SCREENING FOR CELIAC DISEASE AND T1D
12:30-12:45 European Perspective - Daniel Agardh
12:45-1:00 U.S. Perspective - Edwin Liu
1:00-1:15 Parental Perspective – Rachel Karban
1:15-1:30 Panel discussion
SESSION 11: SCREENING FOR PRE-SYMPTOMATIC T1D IN ADULTS
1:30-1:45 Current landscape – Rifka Schulman-Rosenbaum
1:45-2:00 Differences in risk of progression and attitudes between adults and children - M Pauley
2:00-2:15 Perspective of an adult identified by screening - TBN
2:15-2:30 Panel discussion
2:30-2:45 Coffee break
SESSION 12: FUTURE DIRECTIONS
2:45-3:00 USPSTF – Aaron Turner-Phifer
3:00-3:15 Bright Futures and AAP - Jennifer Barker
3:15-3:30 Coordination of efforts – Sanjoy Dutta
3:30-4:00 Panel discussion
|
|---|
| 4:00 Adjourn |
|
|---|
